Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects

Trial Profile

Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Nintedanib (Primary) ; Bosentan
  • Indications Bladder cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Idiopathic pulmonary fibrosis; Liver cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours; Systemic scleroderma
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 18 Mar 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top